



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## BMS-582949 hydrochloride

|                    |                                                                                     |
|--------------------|-------------------------------------------------------------------------------------|
| Cat. No.:          | HY-14305A                                                                           |
| CAS No.:           | 912806-16-7                                                                         |
| Molecular Formula: | C <sub>22</sub> H <sub>27</sub> ClN <sub>6</sub> O <sub>2</sub>                     |
| Molecular Weight:  | 442.94                                                                              |
| Target:            | p38 MAPK; Autophagy                                                                 |
| Pathway:           | MAPK/ERK Pathway; Autophagy                                                         |
| Storage:           | 4°C, sealed storage, away from moisture                                             |
|                    | * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



### SOLVENT & SOLUBILITY

|                                                                               |                                                          |                                      |           |            |            |
|-------------------------------------------------------------------------------|----------------------------------------------------------|--------------------------------------|-----------|------------|------------|
| In Vitro                                                                      | DMSO : 25 mg/mL (56.44 mM; Need ultrasonic)              |                                      |           |            |            |
|                                                                               | Preparing Stock Solutions                                | <div>Solvent<br/>Concentration</div> | Mass      |            |            |
|                                                                               |                                                          |                                      | 1 mg      | 5 mg       | 10 mg      |
|                                                                               |                                                          | 1 mM                                 | 2.2576 mL | 11.2882 mL | 22.5764 mL |
|                                                                               |                                                          | 5 mM                                 | 0.4515 mL | 2.2576 mL  | 4.5153 mL  |
|                                                                               |                                                          | 10 mM                                | 0.2258 mL | 1.1288 mL  | 2.2576 mL  |
| Please refer to the solubility information to select the appropriate solvent. |                                                          |                                      |           |            |            |
| In Vivo                                                                       | 1. Add each solvent one by one: 10% DMSO >> 90% corn oil |                                      |           |            |            |
|                                                                               | Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution        |                                      |           |            |            |

### BIOLOGICAL ACTIVITY

|                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                             |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Description               | BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC <sub>50</sub> of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease <sup>[1]</sup> .                                                                                                                                                                                                                       |                                             |
| IC <sub>50</sub> & Target | p38α MAPK<br>13 nM (IC <sub>50</sub> )                                                                                                                                                                                                                                                                                                                                                                                                                                                       | TNFα<br>50 nM (IC <sub>50</sub> , in cells) |
| In Vitro                  | BMS-582949 displays a p38α IC <sub>50</sub> of 13 nM and a cellular TNFα IC <sub>50</sub> of 50 nM <sup>[1]</sup> .<br>BMS-582949 is a weak inhibitor of CYP3A4 BMS-582949 displays >2000-fold selectivity for p38α over a diverse panel of 57 kinases that include serine kinases, nonreceptor tyrosine kinases, receptor tyrosine kinases, and the p38γ and δ isoforms <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |                                             |
| In Vivo                   | BMS-582949 (5-100 mg/kg, orally) is effective in both the acute murine model of inflammation and rat adjuvant arthritis model despite its slightly reduced potency <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.                                                                                                                                                                                                       |                                             |

|                 |                                                                                                                         |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|
| Animal Model:   | Male Sprague-Dawley rats (250-300 g) adjuvant arthritis model <sup>[1]</sup> .                                          |
| Dosage:         | 1, 10, 100 mg/kg.                                                                                                       |
| Administration: | Orally once daily (from day 11 to day 19).                                                                              |
| Result:         | Displayed dose-dependent reduction in paw swelling with qd dosing, with efficacy observed at doses of 10 and 100 mg/kg. |

## CUSTOMER VALIDATION

- Oncol Res. 2021 Feb 11.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Liu C, et al. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38 $\alpha$  MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem. 2010 Sep 23;53(18):6629-39.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA